1. Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability 
Nayan G. Solanki, Md Tahsin, Ankita V. Shah, Abu T.M. Serajuddin 
Journal of Pharmaceutical Sciences 
Volume 107, Issue 1, Pages (January 2018)
DOI: /j.xphs
Copyright © 2018 American Pharmacists Association® Terms and Conditions

2. Figure 1
Drug release from crushed extrudates of drug-polymer or drug-polymer-polymer mixture containing 10% w/w haloperidol at (a) pH 2 and (b) 6.8. The symbols used for dissolution profiles in (b) are the same as those in (a). Each point refers to mean ± SD (n = 3).
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

3. Figure 2
DSC scans and PXRD patterns of haloperidol-Kollidon® VA64 binary mixtures are given in (a) and (b), respectively. Similarly, DSC scans and PXRD patterns of haloperidol-Affinisol™ 15 cP binary mixtures are shown in (c and d), respectively. Results for both freshly prepared films (Day 1) and after exposure to 40°C/75% RH for 30 days (Day 30) are depicted.
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

4. Figure 3
(a) DSC scans and (b) PXRD patterns of Kollidon® VA64-Affinisol™ 15 cP binary mixture and haloperidol-Kollidon® VA64-Affinisol™ 15 cP ternary mixtures of freshly prepared films (Day 1) and after exposure to 40°C/75% RH for 30 days (Day 30).
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

5. Figure 4
TG analyses of haloperidol and haloperidol-Kollidon® VA64-Affinisol™ 15 cP (10:45:45) ternary physical mixture and crushed extrudates. The initial weights of the physical mixture and the crushed extrudate were set at 100%. In the overlay in figure, the scans are shown separately for better clarity. The weight loss for each sample is proportional.
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

6. Figure 5
Temperature sweep analysis of Kollidon® VA64, Affinisol™ 15 cP, binary mixtures of haloperidol-Kollidon® VA64, haloperidol-Affinisol™ 15 cP, Kollidon® VA64-Affinisol™ 15 cP, and ternary mixture of haloperidol-Kollidon® VA64-Affinisol™ 15 cP at angular frequency of 0.1 rad/s and oscillation strain of 0.5% from 190°C to 130°C. Each data point represents the mean of 2 determinations.
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

7. Figure 6
Photographs of FDM 3D printed tablets, where 1 and 2 are, respectively, haloperidol-Kollidon® VA64-Affinisol™ 15 cP (10:45:45) tablets at 100% and 60% infill, whereas 3 and 4 are, respectively, haloperidol-Kollidon® VA64-Affinisol™ 15 cP (20:40:40) tablets at 100% and 60% infill. Both diameter and thickness of each tablet is shown (a and b, respectively).
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

8. Figure 7
In vitro drug release profiles at (a) pH 2 and (b) pH 6.8 from physical mixtures, crushed extrudates, and 3D printed tablets (100% and 60% infill) containing 10:45:45 w/w haloperidol-Kollidon® VA64-Affinisol™ 15 cP mixtures (10% w/w haloperidol). Each point refers to mean ± SD (n = 3).
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions

9. Figure 8
In vitro drug release profiles at (a) pH 2 and (b) pH 6.8 from physical mixtures, crushed extrudates, and 3D printed tablets (100% and 60% infill) containing 20:40:40 w/w haloperidol-Kollidon® VA64-Affinisol™ 15 cP mixtures (20% w/w haloperidol). Each point refers to mean ± SD (n = 3).
Journal of Pharmaceutical Sciences  , DOI: ( /j.xphs )
Copyright © 2018 American Pharmacists Association® Terms and Conditions